Recent Updates
Recently added Catalysts

Aquestive Therapeutics, Inc.

AQSTFDA catalysts, PDUFA dates & pipeline intelligence
$3.7
▼ -0.06 · -1.6%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full AQST financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $2.9352W HIGH $6.74
Volume
2.12 M
Value Traded
7.87 M
Short % Float
26.65%
Days to Cover
13.2
+3.35%Week
-3.39%1 Month
-19.39%3 Month
-11.27%6 Month
+18.05%5 Year
-72.62%All Time

Cash Data

Unlock AQST cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
465.04 M
EPS (TTM)
-0.63
P/E Ratio
-
Ent. Value
429.70 M
Total Shares
125.69 M
Float Shares
110.03 M
Insiders
12.46%
Institutions
48.72%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
PDUFA Date
Anaphylm (dibutepinephrine) sublingual film (AQST-109)
Type I allergic reactions, including anaphylaxis
Fast Track
PDUFASmall MoleculesUnknown
Unlock every AQST catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

AQST Catalyst Timeline

Dated clinical, regulatory and corporate events for Aquestive Therapeutics, Inc.

Catalyst Timeline

Dated clinical, regulatory & corporate events for Aquestive Therapeutics, Inc.

623Total events
16Upcoming
154Tier-1 (high impact)
2018 to 2037Coverage

Upcoming catalysts 2

T2Product Launch
Subscribe to view catalyst details
LibervantApproved
T1FDA Approval
Subscribe to view catalyst details
LibervantApproved

Event history 50

●R&D DayPresentation
Investor conference call on Q3 2026 results
●Quarterly UpdateCorporate
Aquestive reports third quarter 2026 financial results
▲FDA Filing AcceptedAnaphylmFiledRegulatory Filing
FDA accepts Anaphylm NDA resubmission as complete
Type I allergic reactions, including anaphylaxissource ↗
▲Partnership / LicenseLibervantApprovedCorporate
Eton granted exclusive U.S. commercialization rights to Libervant
seizure clusterssource ↗
●NDA SubmissionAnaphylmFiledRegulatory Filing
Aquestive resubmits NDA to FDA for Anaphylm (dibutepinephrine) sublingual film
Type I allergic reactions, including anaphylaxissource ↗
●sNDA SubmissionAnaphylmFiledRegulatory Filing
Resubmission of NDA to FDA for Anaphylm (dibutepinephrine) sublingual film
Type I allergic reactions, including anaphylaxissource ↗
●NDA SubmissionAnaphylmFiledRegulatory Filing
Anaphylm NDA resubmitted to FDA
type I allergic reactions, including anaphylaxissource ↗
▲FDA Filing AcceptedAnaphylmFiledRegulatory Filing
FDA accepted Anaphylm NDA resubmission as complete
type I allergic reactions, including anaphylaxissource ↗
●Quarterly UpdateCorporate
Reported Q2 2026 financial results
▲Trial CompletionAnaphylmFiledTrial
Completed human factors validation study for Anaphylm
anaphylaxissource ↗
Unlock the full AQST catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How AQST actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
2026-09-30Anaphylm (dibutepinephrine) Sublingual Film (AQST-109) NDA Submission NDA
Unlock 10 more AQST historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

Pipeline Score
Pipeline Value
Commercial Value
Valuation Signal
1
Drugs Scored
rNPV / MCap
Top Drug
Top 24%
Micro Cap
(rank 175 of 725)
Percentile Rank
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Sep 2026)
Showing 4 of 5 assets
DrugIndicationPhasePTRSrNPVStatusEnrollVelocityDesignEst. CompletionML SignalLast Change
DESF Small MoleculesCompletedNCT07703982Allergic ReactionPhase 2 COMPLETED 68May 21, 2025
Diazepam Buccal Soluble Film 5, 7.5,10, 12.5,15 or with individual dose determined according to age and weight category Small MoleculesMarketedNCT03428360EpilepsyApproved COMPLETED 149Jun 25, 2020
Ondansetron Small MoleculesNot countedNCT01217190Nausea and Vomiting, PostoperativePhase 1/2 COMPLETED 48Oct 6, 2008
Diazepam Buccal Film Small MoleculesMarketedNCT03953820EpilepsyApproved COMPLETED 90Jul 31, 2019
Unlock the AQST pipeline intelligence model
PTRS, rNPV, enrollment velocity, trial design quality and ML risk signals for every asset above.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every AQST program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
Anaphylm™ (epinephrine) Sublingual Film severe allergic reactions, including anaphylaxis2025-06-25Elicits Rapid and Consistent Pharmacokinetic and Pharmacodynamic ResponsesRead MoreAquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies of Anaphylm™ (epinephrine) Sublingual Film at the CFAAR Food Allergy SummitRead More
Scroll for more · summaries link to the source press release
Unlock every AQST trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock AQST insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
Davis Matthew W.Officer (Chief Development Officer)Sell -7,197 87,500 held$3.55 11/12/2026
Unlock the full AQST insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Fund % of Portfolio Current MV Shares Owned Activity
RTW INVESTMENTS, LP 0.3 % 34.38 M 7.43 M
Unlock every fund holding AQST
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in AQST
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see AQST ownership
Insider and institutional ownership, quarter by quarter.

AQST Short Interest

Shares sold short, counted twice a month.

26.65%
Short % of Float
of tradable shares sold short
29.3M
Shares Sold Short
+6.2% vs prior count
13.2 Very high
Days to Cover
trading days of normal volume to buy every short share back
2.2M
Avg Daily Volume
the average used for days to cover
Unlock AQST short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Option Volume

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
2026-11-20
Unlock AQST option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live AQST option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock AQST options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How AQST ranks across every disease it competes in

Competitive Position is a premium feature
See how AQST ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

AQST News

AQST
Nov 9, 2026
AQSTConferences/Events

Aquestive Therapeutics to Present at the Jefferies Global Healthcare Conference

Aquestive Therapeutics announced its participation in the Jefferies Global Healthcare Conference from November 16-19. The management team will present on November 16 at 10:00 am GMT and will conduct one-on-one investor meetings. A webcast of the presentation will be available for 30 days following the event.

Read more →
AQST
Nov 5, 2026
AQSTConferences/Events

Aquestive Therapeutics to Present Data at the 2026 ACAAI Annual Meeting

Aquestive Therapeutics will present multiple studies at the 2026 ACAAI Annual Meeting. Key presentations include pharmacokinetic evaluations of Anaphylm™ (dibutepinephrine) sublingual film. The product aims to provide a novel oral treatment for severe allergic reactions. The meeting will take place from November 12-16, 2026, in Phoenix, Arizona.

Read more →
AQST
Nov 3, 2026
AQSTFDA Updates

Aquestive Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

Aquestive Therapeutics reported its third quarter 2026 financial results, highlighting the acceptance of the Anaphylm NDA resubmission with a PDUFA goal date of March 16, 2027. The company is preparing for a potential U.S. launch of Anaphylm, the first oral medication for severe allergic reactions. Additionally, AQST-108 is advancing in clinical trials for atopic dermatitis.

Read more →
AQST
Oct 27, 2026
AQSTGeneral

Aquestive Therapeutics to Report Third Quarter 2026 Financial Results and Recent Business Highlights on November 3 and Host Conference Call on November 4 at 8:00 a.m. ET

Aquestive Therapeutics will report its third quarter 2026 financial results on November 3, 2026. A conference call for investors is scheduled for November 4, 2026, at 8:00 a.m. ET. The company is known for its innovative delivery technologies and is advancing treatments for allergic reactions and dermatological conditions.

Read more →
AQST
Oct 15, 2026
AQSTFDA Updates
▼ -11.9%on this news

Aquestive Therapeutics Announces FDA Acceptance of Anaphylm™ NDA Resubmission and PDUFA Goal Date of March 16, 2027

Aquestive Therapeutics announced that the FDA has accepted its resubmission of the New Drug Application for Anaphylm, a sublingual film intended for treating Type I allergic reactions. The FDA has set a PDUFA goal date of March 16, 2027, for the review. If approved, Anaphylm would be the first oral medication for severe allergic reactions, addressing a significant unmet need.

Read more →
AQST
Sep 29, 2026
AQSTGeneral

Aquestive Therapeutics Strengthens Board of Directors with Appointment of Richard Daly

Aquestive Therapeutics has appointed Rich Daly to its Board of Directors, effective October 14, 2026. Daly, a seasoned executive with over 30 years in the life sciences sector, will contribute his extensive experience in commercial launches and organizational development. His addition is seen as a strategic move as the company prepares for the potential launch of its product Anaphylm.

Read more →
AQST
Sep 17, 2026
AQSTFDA Updates

Aquestive Therapeutics Announces Resubmission of New Drug Application to FDA for Anaphylm™ (dibutepinephrine) Sublingual Film

Aquestive Therapeutics has resubmitted its New Drug Application for Anaphylm™ (dibutepinephrine) sublingual film to the FDA for treating Type I allergic reactions. The resubmission follows positive results from human factors and pharmacokinetic studies. The FDA will determine the classification and review timeline of the resubmission after its initial review.

Read more →
AQST
Sep 1, 2026
AQSTConferences/Events

Aquestive Therapeutics to Participate in Upcoming September Investor Conferences

Aquestive Therapeutics will participate in four investor conferences in September 2026, including the Wells Fargo Healthcare Conference and the H.C. Wainwright 27th Annual Global Investor Conference. The management team will host meetings and present key information about their innovative medicines. Webcasts of the events will be accessible for 30 days post-conference.

Read more →
AQST
Aug 11, 2026
AQSTFDA Updates

Aquestive Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Aquestive Therapeutics completed required studies for its Anaphylm drug candidate and plans to resubmit the application to the FDA in the third quarter of 2026. The company also manufactured approximately 48 million doses in the second quarter, up from 37 million doses a year earlier. These updates accompany the firm's second quarter 2026 financial results and business progress report.

Read more →
AQST
Aug 10, 2026
AQSTFDA Updates
▲ +8.9%on this newsshared move

Aquestive Therapeutics Announces Positive Topline Human Factors and Pharmacokinetic Study Results for Anaphylm™ (dibutepinephrine) Sublingual Film

Aquestive Therapeutics announced positive results from its human factors and pharmacokinetic studies for Anaphylm™ (dibutepinephrine) sublingual film. The studies support the planned resubmission of the New Drug Application (NDA) to the FDA in Q3 2026. Key improvements include faster pouch opening and reduced incorrect film placement, enhancing usability for patients at risk of anaphylaxis.

Read more →
AQST
Jul 29, 2026
AQSTGeneral

Aquestive Therapeutics to Report Second Quarter 2026 Financial Results and Recent Business Highlights on August 11 and Host Conference Call on August 12 at 8:00 a.m. ET

Aquestive Therapeutics will report its second quarter 2026 financial results on August 11, 2026, and host a conference call for investors on August 12. The company is focused on advancing its product candidates, including Anaphylm™ and AQST-108, which target severe allergic reactions and dermatological conditions. A live webcast of the call will be available on its website.

Read more →
AQST
Jul 7, 2026
AQSTConferences/Events

Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism

Aquestive Therapeutics will participate in the Leerink Partners Therapeutics Forum on July 14, 2026, focusing on immunology and metabolism. The management team will also host one-on-one investor meetings. The company is known for its innovative delivery technologies and is advancing treatments for severe allergic reactions and dermatological conditions.

Read more →
AQST
May 13, 2026
AQSTGeneral

Aquestive Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

Aquestive Therapeutics reported strong financial results for Q1 2026, with a revenue increase of 66% year-over-year. The company reaffirmed its plans to resubmit the Anaphylm NDA in Q3 2026 after a successful FDA Type A meeting. Additionally, AQST-108's phase 1 study showed no safety issues, supporting its potential in treating dermatological conditions. A new $150 million debt facility enhances the company's financial position for upcoming initiatives.

Read more →
AQST
May 12, 2026
AQSTGeneral

Aquestive Therapeutics Completes $150 Million Debt Refinancing with Oaktree

Aquestive Therapeutics has successfully refinanced its debt with a new $150 million facility from Oaktree Capital Management. This refinancing will support the potential launch of Anaphylm, an investigational treatment for severe allergic reactions, pending FDA approval. The new agreement reduces the company's principal debt repayments significantly and provides additional capital for growth.

Read more →
AQST
May 6, 2026
AQSTConferences/Events

Aquestive Therapeutics to Report First Quarter 2026 Financial Results and Recent Business Highlights on May 13 and Host Conference Call on May 14 at 8:00 a.m. ET

Aquestive Therapeutics will report its first quarter 2026 financial results on May 13, 2026, and host a conference call for investors on May 14, 2026. The company aims to provide updates on its business developments and product candidates, including Anaphylm and AQST-108. A live webcast will be available for interested parties.

Read more →
AQST
Mar 30, 2026
AQSTFDA Updates

Aquestive Therapeutics Announces Completion of Type A Meeting with FDA for Anaphylm™ (dibutepinephrine) Sublingual Film

Aquestive Therapeutics has completed a Type A meeting with the FDA regarding the resubmission of its NDA for Anaphylm, a sublingual film for treating Type 1 allergic reactions. The company received valuable feedback on pharmacokinetic and human factor study designs, which will aid in their upcoming studies. The NDA resubmission is planned for Q3 2026, with further regulatory submissions also progressing in Canada and the EU.

Read more →
AQST
Mar 20, 2026
AQSTGeneral

Aquestive Therapeutics Announces New Role of Lori J. Braender and Appointment of Thomas A. Zalewski as Chief Legal Officer and Chief Compliance Officer

Aquestive Therapeutics has appointed Thomas A. Zalewski as Chief Legal Officer and Chief Compliance Officer, effective April 2, 2026. He succeeds Lori J. Braender, who will remain as Corporate Secretary after nearly eight years in her previous roles. Zalewski's extensive experience in life sciences law is expected to support the company's mission, particularly in advancing Anaphylm, an oral epinephrine medication.

Read more →
AQST
Mar 9, 2026
AQSTGeneral

Aquestive Therapeutics Announces Grant of Inducement Award Pursuant to Nasdaq Listing Rule 5635(c)(4)

Aquestive Therapeutics granted Chief Medical Officer Matthew Greenhawt an inducement award of 75,000 restricted stock units and 50,000 stock options. The Compensation Committee approved these equity awards under the company’s 2022 Equity Inducement Plan. The grants rely on the Nasdaq Listing Rule 5635(c)(4) exemption for new hires. Vesting occurs over three years based on continued employment.

Read more →
AQST
Mar 5, 2026
AQSTGeneral

Aquestive Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Aquestive Therapeutics reported its financial results for Q4 and full year 2025, highlighting progress on Anaphylm, an oral epinephrine medication. The company received a Complete Response Letter from the FDA, necessitating further studies before resubmission. Despite challenges, Aquestive remains optimistic about Anaphylm's potential, bolstered by new leadership and a growing allergy market.

Read more →
AQST
Feb 25, 2026
AQSTConferences/Events

Aquestive Therapeutics to Participate in Upcoming March Investor Conferences

Aquestive Therapeutics announced its participation in four investor conferences in March 2026. The company aims to showcase its advancements in innovative medicines and delivery technologies. A webcast of the presentations will be available for 30 days post-event. The company is known for its proprietary products and contract development services.

Read more →

About Aquestive Therapeutics, Inc.

Warren, NJ 147 employees aquestive.com
Headquarters184 LIBERTY CORNER ROAD, WARREN, NJ
Founded2004
BIOPHARMAWATCH ELITE
Trade the next AQST catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime